Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimizing MATRix as remission induction in primary central nervous system lymphoma
2018-002115-96Phase 3Active
- Sponsor
- Klinikum Stuttgart
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab, methotrexate, cytarabine, thiotepa, carmustine and 1 more in primary central nervous system lymphoma (PCNSL) and Diffuse Large B-Cell Primary Central Nervous System Lymphoma (2 arms), sponsored by Klinikum Stuttgart. Primary endpoint: Event-free survival. Started Jan 2021; status: active.
02
Drugs
rituximabmethotrexatecytarabinethiotepacarmustine
03
Conditions
primary central nervous system lymphoma (PCNSL)Diffuse Large B-Cell Primary Central Nervous System Lymphoma
Beyond the preview
Go deeper on 2018-002115-96.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002115-96.